FDA approves first in class targeted therapy for metastatic pancreatic cancer
The FDA has granted accelerated approval to Rasonque, a new targeted therapy for patients with metastatic pancreatic adenocarcinoma. The drug acts as a RAS inhibitor, offering a new treatment option for a historically difficult-to-treat cancer.
Why it matters
This approval provides a significant medical advancement for a cancer type with historically poor survival rates and limited treatment options.
The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.
This action demonstrates the agency’s commitment to moving with urgency, reducing unnecessary delays and advancing innovative treatments that can make a meaningful difference in the lives of American patients and their families.
Rasonque, a tablet taken once daily, targets multiple forms of a protein called RAS, a key driver of tumor growth in most patients with pancreatic adenocarcinoma, which arises from cells lining the ducts of the pancreas.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in